Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction?
JACC Heart Fail
; 12(7): 1157-1165, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38878010
ABSTRACT
As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of mortality and development of heart failure (HF) following acute myocardial infarction (MI). Despite this, the development of chronic HF remains a common occurrence in the days, months, and years following MI. Neurohormonal inhibition remains the mainstay of pharmacologic prevention of HF following MI, with recent trials showing an additive benefit of a neprilysin inhibitor or a sodium glucose co-transporter 2 inhibitor in reducing the risk of development of HF but no significant effect on mortality. Novel imaging tools may help refine risk stratification in high-risk patients and allow greater targeting of preventative therapies in patients most likely to benefit. Research is ongoing into novel therapies aiming to minimize the degree of myocardial damage and prevention of progressive adverse remodeling following MI.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Heart Failure
/
Myocardial Infarction
Limits:
Humans
Language:
En
Journal:
JACC Heart Fail
Year:
2024
Type:
Article
Affiliation country:
United kingdom